Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: HSIC stock price vs ILMN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ILMN's multiple
Needs ILMN P/E.
Implied fair value · at HSIC's multiple
Needs HSIC P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
HENRY SCHEIN, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
ILLUMINA, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
CARDINAL HEALTH INC
HSIC vs CAH
DANAHER CORP /DE/
HSIC vs DHR
PATTERSON COMPANIES, INC.
HSIC vs PDCO
QUEST DIAGNOSTICS INC
HSIC vs DGX
WEST PHARMACEUTICAL SERVICES INC
HSIC vs WST
BAXTER INTERNATIONAL INC
HSIC vs BAX
THERMO FISHER SCIENTIFIC INC.
HSIC vs TMO
AGILENT TECHNOLOGIES, INC.
HSIC vs A
BIO-RAD LABORATORIES, INC.
HSIC vs BIO
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
HSIC vs PACB
Natera, Inc.
HSIC vs NTRA
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe HSIC can sustainably expand margins and defend its 4.0% revenue growth, then the stock deserves a constructive view because its 26.2x P/E and 0.7x P/S are well below ILMN’s much richer multiples; otherwise, the current price already looks rich versus the DCF range.
HSIC trades at a large valuation discount to ILMN on both earnings and sales-based measures, but the gap is partly explained by ILMN’s far stronger profitability profile. HSIC’s current price of $85.75 sits below its ILMN-implied value of $123.06, yet still above the top of the DCF range and near the upper end of the historical band.
Supporting Metrics
